Malignant Mesothelioma (MM) is a relatively common, rapidly progressive and treatment-resistant malignancy linked to asbestos exposure. Both human MM patients and mouse models of this devastating disease show frequent loss of the neurofibromatosis type II tumor suppressor gene, Nf2, and re-expression of Nf2 in Nf2-null MM cells inhibits their proliferation/viability and restrains their motility, implying that Nf2 los plays a fundamental role in MM pathogenesis. Previously, we and others have implicated Merlin, the protein product of the Nf2 gene, in the regulation of p21-activated kinase (Pak) and mammalian sterile twenty-like (Mst) signaling. These two STE20 kinases play an important role in regulating cell proliferation, survival, adhesion, motility, spreading and invasiveness ? properties connected with the malignant phenotype of Nf2-deficient MM cells. We postulate that both pathways are essential for MM tumorigenesis associated with NF2 loss, and that both pathways can be exploited for therapeutic benefit. We propose two aims.
In Aim 1 we will determine the response of a Nf2-null MM mouse model to potent, newly developed preclinical Pak small molecule inhibitors. As we expect that aggressive cancers such as MM will adapt and eventually evade single targeted agents such as Pak inhibitors, we also propose to use a newly developed technology to globally measure the activity of all protein kinases prior to and during treatment with anti-Pak agents, with the goal of identifying potential secondary drug targets for combination therapy.
In Aim 2 we plan to delineate the role of the Mst, the defining element in the Hippo tumor suppressor pathway, in Merlin- related signaling and pathology in vivo. Using cell-based assays, we will determine the mechanism by which Merlin controls Mst activity, focusing on our recent observation that loss of Merlin induces a switch from active Mst1/Mst1 and Mst2/Mst2 homodimers to inactive Mst1/Mst2 heterodimers. We will also assess the suitability of targeting the Hippo pathway in MM by crossing our MM mouse model into a conditional Yap1-null strain to assess the effects on Yap loss on tumor incidence and progression. The proposed studies will not only increase our understanding of cardinal oncogenic signaling pathways, but could establish Pak and Mst kinases as suitable targets for therapeutic intervention in this otherwise untreatable disease.

Public Health Relevance

As there is currently no effective medical therapy for MM, a deadly disease associated with asbestos exposure and loss of the NF2 gene, understanding how NF2 functions in cell proliferation, survival, motility, and invasion is a key strategy to idenify signaling pathways that might provide useful drug targets in this disease. The NF2 protein product, Merlin, affects the activity of two STE20 kinases: p21-activated kinases (Pak) and mammalian Sterile twenty (Mst). Because activated Pak and YAP (a target of Mst) are themselves oncogenic, and, unlike Merlin, are amenable to inhibition by small molecules, we are in a unique position to explore the biological role of these proteins in MM and to determine if they represent suitable targets for therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA148805-06
Application #
9106800
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Ault, Grace S
Project Start
2011-03-01
Project End
2021-03-31
Budget Start
2016-04-22
Budget End
2017-03-31
Support Year
6
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Joseph, Giselle A; Lu, Min; Radu, Maria et al. (2017) Group I Paks Promote Skeletal Myoblast Differentiation In Vivo and In Vitro. Mol Cell Biol 37:
Semenova, Galina; Stepanova, Dina S; Deyev, Sergey M et al. (2017) Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1. Biochimie 135:1-5
Semenova, Galina; Chernoff, Jonathan (2017) Targeting PAK1. Biochem Soc Trans 45:79-88
Stepanova, Dina S; Semenova, Galina; Kuo, Yin-Ming et al. (2017) An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Res 77:5026-5038
Tan, Yinfei; Sementino, Eleonora; Chernoff, Jonathan et al. (2017) Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. Am J Cancer Res 7:1724-1737
Prudnikova, Tatiana Y; Chernoff, Jonathan (2017) The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases 8:193-198
Rawat, Sonali J; Araiza-Olivera, Daniela; Arias-Romero, Luis E et al. (2016) H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization. Curr Biol 26:1556-1563
Borczuk, Alain C; Pei, Jianming; Taub, Robert N et al. (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17:328-35

Showing the most recent 10 out of 28 publications